Hyundai Bioscience desarrolla XAFTY®, un medicamento antiviral de amplio espectro en ensayos Fase 3 para COVID-19, mpox y dengue. Hyundai Bioscience develops XAFTY®, a broad-spectrum antiviral drug in Phase 3 trials for COVID-19, mpox, and dengue.

Hyundai Bioscience ha desarrollado XAFTY®, un medicamento antiviral de amplio espectro dirigido a COVID-19, mpox y dengue. Hyundai Bioscience has developed XAFTY®, a broad-spectrum antiviral drug targeting COVID-19, mpox, and dengue. En la Cumbre de Prevención y Control de Enfermedades 2024 en Filadelfia, la empresa informó que XAFTY® se deriva de niclosamida y actualmente se encuentra en ensayos Fase 3 para COVID-19, centrándose en pacientes de alto riesgo. At the Disease Prevention and Control Summit 2024 in Philadelphia, the company reported that XAFTY® is derived from niclosamide and is currently in Phase 3 trials for COVID-19, focusing on high-risk patients. El medicamento es particularmente notable por su eficacia contra el mpox y el dengue, condiciones sin tratamientos existentes, y se están llevando a cabo discusiones para acelerar su disponibilidad. The drug is particularly notable for its effectiveness against mpox and dengue, conditions with no existing treatments, and discussions are ongoing to expedite its availability.